by Crestone, Inc. | Mar 9, 2026 | Press Releases
Both dosages of CRS3123 showed excellent efficacy at the day 12 test-of-cure visit, hitting the primary endpoint CRS3123 had lower rates of recurrence (e.g., 4% for the combined CRS3123 dosages versus 23% for vancomycin at day 40), addressing the primary unmet medical...
by Crestone, Inc. | Jan 22, 2026 | Peer-Reviewed Publication
A landmark Phase 2 randomized controlled trial demonstrates the safety, tolerability, and promising efficacy of CRS3123 as a novel treatment for Clostridioides difficile infection. | The Lancet Infectious Diseases • January 22, 2026 “Both doses of CRS3123 were deemed...
by Crestone, Inc. | Jul 16, 2025 | Events
Crestone had the opportunity to showcase its innovative research at two prestigious conferences: the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia. These presentations highlighted CRS3123, a narrow spectrum agent designed for the treatment...
by Crestone, Inc. | Jul 11, 2025 | Events
Crestone made a significant impact at the ASM Microbe 2025 conference in Los Angeles by presenting groundbreaking research on microbiome analysis. Their presentation, delivered by Dr. Oren Gordon, focused on a Phase 2 clinical trial that compared CRS3123, one of their...
by Crestone, Inc. | Jul 11, 2025 | Events
Crestone showcased their innovative work at the ESCMID Global conference in Vienna on April 15, 2025. Delivered by Dr. Jon Brus, the highlight of their presentation was CRS3123, a groundbreaking treatment demonstrating high cure rates and low recurrence in addressing...
